AARD NASDAQ
Credit Risk of going bust: higher than 91% of companies Debt: 2.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.02 (down 99%), Aardvark Therapeutics, Inc. Common Stock would be worth roughly what it owes.
Total debt $677K against a stock market value of $28.5M.
Distance to default 1.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $539K (short-term plus half of long-term), stock volatility 173.6%; Altman Z'' 5.92. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
San Diego, CA 92122
US
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Zhang Zhongwei | A-Award | 127,061 | $4.96 | 2026-10-07 |
| Zhang Zhongwei | 0 | — | 2026-10-07 | |
| Sun Nelson | S-Sale | 62,000 | $5.18 | 2026-09-11 |
| Sun Nelson | S-Sale | 14,754 | $5.00 | 2026-09-10 |
| Graf Susan E | A-Award | 44,964 | $6.54 | 2026-08-14 |